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Background. In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier
studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the
prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and
exclusions. Methodology/Principal Findings. The aim of the study was to assess the age-standardized prevalence of
overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and
nocturia in the absence of urinary tract infection or other obvious pathology. In 2003–2004, a questionnaire was mailed to
6,000 randomly selected Finns aged 18–79 years who were identified from the Finnish Population Register Centre. Information
on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and
nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The
questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The
prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion
of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6%
[CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported
by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of
women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. Conclusions/
Significance. Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies,
occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low
participation.
Citation: Tikkinen KAO, Tammela TLJ, Rissanen AM, Valpas A, Huhtala H, et al (2007) Is the Prevalence of Overactive Bladder Overestimated? A
Population-Based Study in Finland. PLoS ONE 2(2): e195. doi:10.1371/journal.pone.0000195
INTRODUCTION
Research on urinary storage problems has focused on inconti-
nence in women, but during recent years other urinary storage
problems (urgency, frequency, and nocturia) and their treatment
among both sexes has commanded attention worldwide [1].
According to the International Continence Society, overactive
bladder is a symptom-defined condition characterized by urinary
urgency, with or without urgency incontinence, usually with
urinary frequency and nocturia. The term overactive bladder is
appropriate if there is no proven infection or other obvious
pathology [2].
Overactive bladder is a poorly understood disorder [1]. In
earlier reports, overactive bladder impaired quality of life [3,4],
was underdiagnosed and undertreated [3,5–10], and cost more
than $9 billion in the United States in 2000 [4,11]. However, the
value of current overactive bladder treatment with antimuscarinics
(with an increasing market [11% annual growth] worldwide of
more than $2.2 billion in 2005 [12]) was questioned by the
Cochrane Review [13].
Most earlier studies on overactive bladder have reported
a prevalence of 10%–20% [3–7,9,14–16], the most widely cited
studies estimating prevalence of overactive bladder as one in six
[3,4]. Some studies have reported prevalence as high as 30% to
53% [8,10], while one showed only 8% [17], and one as low as 2%
[18]. Unfortunately, all these studies have had methodological
limitations [3,4,6,7,9,14–17] or have not been population-based
[5,8,10,18].
We assessed the prevalence of overactive bladder in a popula-
tion-based study of subjects of both sexes aged 18–79 years.
METHODS
Study design
Between November 2003 and February 2004, a questionnaire was
mailed to a random sample of 3,000 men and 3,000 women aged
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18–79 years drawn from the Finnish Population Register Center.
Stratification by age was used in subject selection, with over-
sampling of the younger age groups to achieve a similar number of
subjects with urgency/overactive bladder even in age groups with
lower prevalence of urgency/overactive bladder (Table S1). We
selected the target level of accuracy so that, given a true prevalence
of 15%, we could exclude a prevalence of 10% or lower.
Information on voiding symptoms was collected using the
validated Danish Prostatic Symptom Score (Table 1) [19]. The
questionnaire included items related to physician-diagnosed co-
morbidity (such as gynecological, internal, mental, musculoskele-
tal, neurological, and/or urological conditions), prescribed med-
ication (over the last 3 months) and socio-demographic factors
(such as marital, educational and employment status). Information
on pregnancy was based on both questionnaire and data from the
Finnish Population Register Center which also provided in-
formation on puerperium and urbanity. Questionnaires were first
mailed in late November 2003, with reminders a month later. To
persons who did not respond, final questionnaire was sent in
February 2004. The last questionnaires were returned in June
2004. In accordance with Finnish regulations on questionnaire
surveys, an exemption from ethical review was granted by the
ethical committee of Tampere University Hospital (Tampere,
Finland).
Exclusions and definitions
In the first analysis (Urgency analysis), we assessed the prevalence
of urgency in adult population without applying any exclusion
criteria (Figure 1). In the main analysis (Overactive bladder
analysis), we assessed the prevalence of overactive bladder in adult
population excluding those with physician-diagnosed: 1) chronic
or acute urinary tract infection (in the past 2 weeks); 2)
genitourinary cancer (excluding renal); or 3) contracted bladder
(due to radiation or painful bladder syndrome), also 4) prescribed
loop diuretics; and 5) pregnant or puerperal women, with
puerperium defined as 6 weeks after childbirth (Table 2). In the
third analysis (OAB without BPH analysis), in addition to above
mentioned exclusions (of Overactive bladder analysis), we
excluded men reporting physician-diagnosed benign prostatic
hyperplasia. We performed a fourth analysis (All OAB symptoms
analysis), to assess the relationship of all symptoms of overactive
bladder with the same exclusions as used in the Overactive bladder
analysis (Figure 1).
The urgency question from the validated Danish Prostatic
Symptom Score was used to assess the prevalence of urgency and
overactive bladder [19]. Overactive bladder with or without
urgency incontinence classification was subdivided into overactive
bladder cases based on the urinary urgency incontinence question
of the Danish Prostatic Symptom Score. The mean daily number
of voids was used for urinary frequency classification, whereas
responses to nocturia questions from the Danish Prostatic
Symptom Score and American Urological Association Symptom
Index were combined [19,20]. The Danish Prostatic Symptom
Score questionnaire was applied for the past 2 weeks, while
frequency question and nocturia question of American Urological
Association Symptom Index pertained to the past month (Table 1).
Statistical analysis
Subjects were stratified into 10-year age groups (18–29, 30–39,
40–49, 50–59, 60–69, and 70–79 years). The age-standardized
prevalence was calculated using the general population of Finland
(end of year 2003) by the Finnish Population Register Centre [21]
(and the European standard population [22]). Binomial regression
with identity link was used with presence of overactive bladder as
outcome for extrapolation of age-specific prevalence of overactive
bladder among people aged 80 years or more. All confidence
intervals were likelihood-based. Confidence Interval Analysis 2.0.0
software (Trevor Bryant, University of Southampton, United
Kingdom) was used for calculating age-standardized prevalences
and confidence intervals (CI). Other analyses were performed
using the Stata 9 (StataCorp LP, College Station, United States).
Adjustment for selection bias due to non-response was made for
each symptom and combination of symptom (urgency, overactive
bladder with or without urgency incontinence, frequency, and
nocturia) after possible exclusions. First, prevalence of symptoms
was calculated by mailing round (defined by date of questionnaire
completion). As the prevalence of symptoms was lower in the
subsequent than in the first round responses, the prevalence
among non-participants (of the eligible study population) was
assumed to be similar to the late responders, using formula:
PNonparticipants~(P2nd round participantszP3rd round participants)=2
where P is prevalence of symptom (urgency, overactive bladder
with or without urgency incontinence, frequency or nocturia).
Hence, based on the number of non-participants and
prevalence of symptoms, we calculated the number of subjects
with each symptom (and combinations in the All OAB symptoms
analysis). The corrected prevalence of symptom was calculated
using the formula:
Pcorrected~(NParticipants|PParticipantszNNonparticipants|
PNonparticipants)=(NParticipantszNNonparticipants)
Table 1. Overactive bladder symptom-related questions and definitions of the study in Finland, 2003–2004
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Symptoms Defining questions (with answer options) Normal Abnormal
Urgency and overactive
bladder*
‘‘Do you experience an imperative (strong) urge to urinate?’’ with answer options:
never-rarely-often-always.
Never or rarely Often or always
Urgency incontinence ‘‘Is the urge so strong that urine starts to flow before you reach the toilet?’’ with
answer options: never-rarely-often-always.
Never or rarely Often or always
Frequency ‘‘How many times did you usually urinate per day during the last month?’’ #8 voids per day .8 voids per day
Nocturia ‘‘How many times do you have to void per night?’’ and ‘‘How many times did
you most typically get up to urinate from the time you went to bed at night
until you got up in the morning?’’ were combined.
#1 void per night .1 void per night
*Urgency classification without any exclusions; overactive bladder classification was performed after exclusion of subjects with urinary tract infection or other obvious
pathology (Table 2).
doi:10.1371/journal.pone.0000195.t001..
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where P is prevalence of symptom (or combination of symptom)
and N is number of subjects.
Concerning analyses for corrected prevalence of symptoms,
we also performed an analysis excluding the same proportion
of subjects among non-participants as we had done among
participants, but the results did not materially change.
RESULTS
Of the 6,000 subjects approached for the study, 3,727 (62.4%)
participated; 23 were unavailable because of serious disability or
disease, death, or emigration (Figure 1). Of all participants, 98.5%
(n= 3670) responded to the Danish Prostatic Symptom Score
urgency question (Urgency analysis). For the assessment of overac-
tive bladder prevalence (Overactive bladder analysis), we excluded
210 participants (Table 2). Most of the included participants
(94.0%) also gave the date of questionnaire completion (Table S1).
To assess the effect of benign prostatic hyperplasia on overactive
bladder (OAB without BPH analysis), we further excluded 114
men. For comparison of all symptoms of overactive bladder, every
Figure 1. Flow chart of the study in Finland, 2003–2004. * OAB, overactive bladder; BPH, benign prostatic hyperplasia; SD, standard deviation.
doi:10.1371/journal.pone.0000195.g001
Table 2. Exclusions of the study population of overactive
bladder analysis: number of excluded subjects among 1725
men and 2002 women in Finland, 2003–2004
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Characteristics Men Women Both sexes
Urinary tract infection* 16 59 75
Genitourinary cancer{ 22 11 33
Contracted bladder{ 2 5 7
Puerperium1 8 8
Pregnancy 49 49
Taking loop-diuretics 19 30 49
Together 54 156 210
*Acute (in past 2 weeks) or chronic urinary tract infection.
{Excluding renal cancer.
{Due to e.g. painful bladder syndrome or radiation.
1Puerperium defined as 6 weeks after childbirth.
doi:10.1371/journal.pone.0000195.t002..
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question on urgency, urgency incontinence, frequency, and
nocturia was answered by 95.2% of subjects (Figure 1).
After age-standardization (to the Finnish general population),
prevalence of urgency was 7.0% (95% CI, 5.9% to 8.1%) for men
and 10.3% (CI, 8.9% to 11.6%) for women. The age-standardised
prevalence of overactive bladder was 6.5% (CI, 5.5% to 7.6%)
for men and 9.3% (CI, 7.9% to 10.6%) for women (Figure 2).
Exclusion of men with benign prostatic hyperplasia decreased the
prevalence of overactive bladder among men to 5.6% (CI, 4.5% to
6.6%). The effect of benign prostatic hyperplasia on the
prevalence of overactive bladder was strongest in elderly with
the prevalence decreasing from 17.5% to 13.5% at age 60–69
years and from 17.6% to 14.0% at age 70–79 years after further
exclusion of men with benign prostatic hyperplasia.
In general, overactive bladder was slightly more common
among women than men after age-standardization (Figure 2). It
was more common among women in younger ages while among
men it was more common in those aged 60 years and above.
Among men, the sharpest increase occurred at age 60–69 years
while among women the increase was more steady. The mean
increases in prevalence of overactive bladder were 2.4 percentage
point (CI, 1.9%-point to 3.0%-point) per 10-year age group for
men and 1.9 percentage point (CI, 1.2%-point to 2.6%-point) per
10 years for women. There was no statistically significant
departure from linearity in either sex (Figure 2).
In the All OAB symptoms analysis (Figure 3), urgency incontin-
ence was reported by 11% of men and 27% of women among
those with overactive bladder. Urinary frequency was reported by
23% of men and 38% of women with overactive bladder whereas
the corresponding figures for nocturia were 56% and 40%. On the
other hand, even though subjects with overactive bladder reported
more frequency and nocturia than subjects without overactive
bladder, only 31% of men and 35% of women with frequency, and
31% of subjects among both sexes with nocturia reported
overactive bladder (Figure 3).
Without corrections for non-response, urgency was reported by
7.9% (CI, 6.5% to 9.3%) of men and 10.7% (CI, 9.0% to 12.3%)
of women after age-standardization. The corresponding figures for
overactive bladder were 7.3% (CI, 5.9% to 8.7%) for men and
9.7% (CI, 8.0% to 11.3%) for women. Further exclusion of men
with benign prostatic hyperplasia decreased the non-corrected
prevalence of overactive bladder to 6.3% (CI, 4.8% to 7.7%)
among men aged 18–79 years.
DISCUSSION
In our study, the prevalence of overactive bladder was 6.5% for
men and 9.3% for women, i.e. no more than 8% of adult
population aged 18–79 years had overactive bladder. Subjects
with overactive bladder reported more frequency and nocturia
than those without overactive bladder, but the majority of subjects
with frequency, or nocturia did not report overactive bladder.
The reported prevalence of overactive bladder has varied widely
in earlier studies due to differences in symptom assessment, study
population, data collection, and definition of overactive bladder
including exclusion criteria. Most other studies have reported
greater prevalence of overactive bladder than found in our study
[3–10,14–16]. Some [3–5,15–17] but not all studies [6] have also
reported more urgency incontinence among subjects with over-
active bladder than we found.
The definition of a symptom-defined disorder, such as over-
active bladder, has a major impact on outcome [23]. We used the
overactive bladder definition of International Continence Society,
with urgency (defined as sudden compelling desire to void) as
a sufficient criterion for overactive bladder [2]. This definition is
idealistic and ambiguous. The qualitative definition disregarding
severity or symptom bother makes it difficult to apply. The classifi-
cation of a symptom (including the time period during which the
occurrence of symptoms is asked) strongly influences the result,
due in part to fluctuating character and very high remission rates
of lower urinary tract symptoms, including urgency [24]. We
asked about urgency in the last 2 weeks with four response option:
if urgency was reported ‘‘never’’ or ‘‘rarely’’, the subject was
classified as normal, while ‘‘often’’ and ‘‘always’’ were regarded as
abnormal. Our classification of urgency differed slightly from the
Austrian study, where a five-point scale was used for the last 4
weeks and subjects who ‘‘occasionally’’ had urgency were also
defined as abnormal [5]. Similarly, in the Chinese community-
based study, women who reported urgency ‘‘occasionally’’ were
Figure 2. The prevalence of overactive bladder in Finland, 2003–2004. The blue bars indicate men with overactive bladder and the red bars women
with overactive bladder. Age-standardization was performed using the general population [21].
doi:10.1371/journal.pone.0000195.g002
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regarded abnormal but only in the presence of other symptoms
(with criteria every 3 hour for frequency, twice per night for
nocturia, and once a week or less frequent for urge incontinence)
[17]. In the US study, those who reported four or more urgency
episodes during the last 4 weeks and who also reported more than
eight voids per day, or at least one coping strategy were classified
as abnormal [4]. Some studies asked symptoms over a very long or
unspecified time [3,9,16,18] whereas some did not exactly describe
symptom classification, questions asked, or time concerning the
symptom question [7,8,10,14,15]. Overall, in all symptom-defined
disorders (including overactive bladder), defining very mild/rare
symptoms as pathological blurs the distinction between mild and
severe, causing a considerable risk of encouraging healthy people
to perceive themselves as sick [25].
In the standardization report [2], the current definition of
overactive bladder includes ‘‘…usually with frequency and
nocturia.’’, and those symptoms are defined as complaints without
any severity assessment. We defined frequency as more than 8
voids per day and nocturia as more than one void per night (as in
some earlier reports [3–5,18]) while those definitions are pre-
sumably clinically more relevant based on prevalences of
frequency and nocturia in earlier studies [9,16,26,27]. On the
other hand, the definition of frequency or nocturia has no effect on
the prevalence of overactive bladder when based on the current
definition.
According to the standardization report [2], for the diagnosis of
overactive bladder subjects with ‘‘urinary infection or other
obvious pathology’’ should be excluded. Identification of over-
active bladder without excluding known reasons causing urgency
can result in overestimate of prevalence. We excluded subjects
with urinary tract infection, genitourinary cancer, contracted
bladder, or loop diuretics, as well as pregnant and puerperal
women. In addition, we performed an analysis excluding men with
benign prostatic hyperplasia as its effect on overactive bladder is
unclear [1]. Some earlier studies did not report any exclusion
criteria [6,8–10,14,16–18], or excluded only subjects with urinary
tract infection [3]. In the Austrian and Brazilian studies [5,7],
exclusions were slightly broader (for example, diabetes) than in our
study and in the US study [4] even more extensive (including
diabetes, congestive heart failure, and excessive fluid intake). In the
Austrian study, exclusions were performed for subjects with
urgency, not for the whole study sample.
Several articles have been published on the prevalence of
overactive bladder (English-language MEDLINE and PubMed
search to December 2006). However, many of these studies have
not been population-based [5,8,10,18], whereas the population-
based studies [3,4,6,7,9,14–17] have failed to: 1) apply the current
definition of overactive bladder [3,4,6,14,15,17], 2) report any
exclusions [6,9,16,17], 3) include all adult ages [3,6,7,9,15], 4)
include both sexes [17], 5) report response rate or non-participants
[3,7,9], or 6) achieve good response rate [4,6,9,16] (Table 3).
Furthermore, none of the earlier studies used non-response
analysis to adjust for selection bias. On the other hand, as long
as the symptom definition of overactive bladder is more like
a description without any severity or bother assessment, there is no
absolutely correct way to study the epidemiology of overactive
bladder.
We used postal questionnaires to assess both the prevalence of
urinary symptoms and co-morbidity. Overactive bladder is
a symptom-defined condition requiring self-report. Mailed ques-
tionnaires reflect urodynamics better than interview-assisted
questionnaire responses [28]. Furthermore, mailed questionnaires
provide more reliable information than telephone surveys in
several aspects, including higher participation [29]. Telephone
surveys have commonly been used, including the most cited figures
[3,4,9,16].
Even though most studies reported higher prevalence estimates
than ours, the differences can be readily explained by dissim-
ilarities in study procedures. For instance, Milsom and colleagues
stated in their multinational study that 16.6% had overactive
Figure 3. Age-standardized prevalence of overactive bladder symptoms among Finnish people aged 18–79 years, 2003–2004. The red circle
represents subjects with overactive bladder without urgency incontinence excluding the area of the red oval representing subjects with overactive
bladder with urgency incontinence. The blue circle represents subjects with urinary frequency (defined as more than eight voids per day) and the
green circle nocturia (defined as more than one void per night). Age-standardization was performed using the general population [21].
doi:10.1371/journal.pone.0000195.g003
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bladder [3]. They did not use the current definition of overactive
bladder and excluded only subjects with urinary tract infection. In
their study (all subjects at least 40 years old) only 54% of subjects
with overactive bladder reported urgency corresponding approx-
imately to 9.0% prevalence of urgency. Hence, based on their
study population 9.0% prevalence of overactive bladder would
also be overestimated due to age distribution and absence of other
exclusion criteria and non-response analysis. This estimate concurs
with our results.
Of the Finnish adult population, 5% are aged 80 years or more
[21]. As our sample did not include this age group, we extrapol-
ated the prevalence rates for people aged 80 years or more. Based
on extrapolated prevalence rates of overactive bladder among this
age group (20.0% for men and 17.5% for women), we calculated
age-standardized prevelance of overactive bladder for men (6.9%)
and women (9.8%). Adjustment for people aged 80 years or more
did not materially change prevalence rates as they were within the
confidence limits of our estimates indicating that one in twelve
(8.4%) had overactive bladder in the general population. However,
our study population was Caucasian, which may diminish general-
izability to other ethnicities. Most reported studies also used a study
population that was mainly or totally Caucasian without proper
comparison of prevalence of overactive bladder between different
ethnicities [3–5,7,9,16,18]. Consequently, there is a need to
examine the effect of ethnic differences on the prevalence of
overactive bladder.
Our aim was to obtain a generalizable, unbiased estimate of the
prevalence of overactive bladder in both genders. Our study
population from youth to old age was representative of Finnish
adults in terms of socio-demographic and anthropometric factors
[27,30] and included people aged 18–79 years. Age-standardiza-
tion was used to improve comparability with other studies and
generalizability to other populations. Current population distribu-
tion of Finland was used so as not to underestimate prevalences.
We calculated corresponding figures also using European standard
population [22], but as the age structure was younger in that, the
prevalence rates were slightly lower (not reported). To further
improve the generalizability, we estimated corrected prevalence of
overactive bladder with adjustment for people aged at least 80
years. After adjustment for people aged 80 years or more, the
results remained substantially the same. A good response rate was
achieved, but to further improve the validity, we estimated the
corrected prevalence of overactive bladder with adjustment for
selection bias due to non-response. We corrected prevalence for
selection bias on the assumption that overactive bladder was
equally common among non-responders and in late responders.
The corrected estimate was smaller, indicating that naı¨ve analysis
overestimates prevalence.
Our results suggest that the prevalence of overactive bladder has
been overestimated so that the true prevalence is approximately
half of that proposed earlier. Overactive bladder affects approx-
imately one out of twelve adults of Caucasian origin.
SUPPORTING INFORMATION
Table S1 Number of subjects in different analyses and in
overactive bladder analysis.
Found at: doi:10.1371/journal.pone.0000195.s001 (0.07 MB
DOC)
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